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1  | INTRODUCTION
Women with type 1 diabetes have a higher risk of infertility compared 
to women without diabetes, even after accounting for the higher prev-
alence of irregular menses among women with type 1 diabetes.1-4 This 
higher risk has been attributed to suboptimal glycemic control4,5 as 
well as the higher prevalence of autoimmune diseases such as thy-
roid disorders among women with type 1 diabetes.6 Women with type 
1 diabetes may also have a high prevalence of polycystic ovary syn-
drome (PCOS), suggested by elevated levels of ovarian markers such 
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Objective: Women with type 1 diabetes have increased risk of infertility compared to 
women without diabetes even after adjustment for irregular menses, but aetiologies 
are incompletely understood. Our aim was to examine the prevalence of abnormalities 
in ovarian markers consistent with polycystic ovary syndrome in women with type 1 
diabetes and associations with irregular menses and diabetes- specific variables.
Design, Patients and Measurements: We conducted a secondary analysis of women in 
the	Diabetes	Control	and	Complications	Trial/Epidemiology	of	Diabetes	Interventions	
and	Complications	Study	(DCCT/EDIC),	a	randomized	trial	and	observational	follow-
 up of intensive insulin therapy for type 1 diabetes. We included women with anti- 
Müllerian	hormone	(AMH)	measurements	among	women	not	using	oral	contraceptives	
(n	=	187).	 Initial	 AMH	 and	 testosterone	 measures	 were	 performed	 between	 EDIC	
years	1	and	4.	History	of	irregular	menses	was	assessed	annually.
Results: The median age of women was 35 (interquartile ratio 29, 40) years; 133 (35%) 
had	elevated	AMH	and	62	(17%)	reported	irregular	menses.	Twelve	per	cent	of	women	
had	relative	elevations	in	total	testosterone.	In	multivariable	models,	lower	insulin	dos-
ages	were	associated	with	higher	AMH	concentrations	(P = .0027), but not diabetes 
duration,	 glycemic	 control,	 body	mass	 index	 or	 irregular	 menses.	 Neither	 irregular	
menses nor diabetes- specific variables were associated with testosterone 
concentrations.
Conclusions:	Among	women	with	 type	1	diabetes	 in	 their	 thirties,	 abnormalities	 in	
ovarian markers are common and not associated with irregular menses and thus may 
partially account for decreased fecundity in women with type 1 diabetes.
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as	anti-	Müllerian	hormone	(AMH)7 and testosterone which are made 
by the gonads.8
Few studies have examined these ovarian markers among women 
with type 1 diabetes after their adolescence and early twenties. For sev-
eral reasons, it is important to examine ovarian markers and predictors 
of	such	markers	at	older	ages.	In	general,	women	are	at	increased	risk	
of infertility as they age, particularly in their thirties or their 4th decade 
of life.9	Due	to	years	of	intensive	insulin	therapy,	women	with	type	1	
diabetes may be particularly vulnerable to obesity as they age.10	Longer	
duration of diabetes and prolonged exposure to elevations in glucose 
could also adversely affect the ovary through deposition of advanced 
glycation end- products.11 Exogenous insulin may also have gonado-
tropic effects,12 particularly because supraphysiologic systemic insulin 
levels are significantly higher in persons with type 1 diabetes due to the 
need to achieve physiologic levels in the portal circulation.13
Therefore, due to previous reports noting increased risk for infer-
tility among women with type 1 diabetes as well as prior reports not-
ing high prevalence of PCOS among women with type 1 diabetes,13 
we	examined	the	prevalence	of	elevations	in	AMH	and	testosterone	
and associations with irregular menses and diabetes- specific variables. 
We conducted a secondary analysis of a large population of well- 
characterized	reproductive-	age	women	(n	=	379	women)	with	type	1	
diabetes with an average of 35 years. We used data from participants 
in	Epidemiology	of	Diabetes	Interventions	and	Complications	 (EDIC)	
study,14	which	is	the	ongoing	observational	follow-	up	to	the	Diabetes	
Control	 and	Complications	Trial	 (DCCT).15	We	hypothesized	 that	 ir-
regular menses as well as longer diabetes duration, higher body mass 
index	(BMI),	poorer	glycemic	control	and	higher	insulin	dosage	would	
be associated with abnormal concentrations in ovarian markers.




compare the impact of intensive vs conventional diabetes treat-
ment on the development and progression of early microvascular 
complications of type 1 diabetes.16 From 1983 to 1989, 1441 pa-
tients (including 680 women) were enrolled at 29 centres. The goal 
of intensive therapy was to maintain glycemic control as close to 
the	nondiabetic	 range	as	possible	using	≥3	daily	 insulin	 injections	
or an insulin pump, with dose adjustment guided by frequent self- 
monitoring of blood glucose. Conventional treatment consisted of 
1- 2 daily insulin injections without stipulated target glucose con-
centrations.	 The	DCCT	 included	 a	 primary	 prevention	 cohort	 and	
a secondary intervention cohort. The primary prevention cohort 
consisted of 726 subjects with no retinopathy, urinary albumin 
excretion rate <40 mg/24 h and diabetes duration of 1- 5 years at 
DCCT	 baseline.	 The	 secondary	 intervention	 cohort	 consisted	 of	
715 subjects who had nonproliferative retinopathy, urinary albumin 
excretion	rate	≤200	mg/24	h	and	diabetes	duration	of	1-	15	years.	
Individuals	were	 excluded	 from	 participating	 in	 the	DCCT	 if	 they	
were hypertensive, taking any blood pressure or lipid- lowering 
medications, or had a history of symptomatic ischaemic heart dis-
ease	 or	 symptomatic	 peripheral	 neuropathy.	 Informed	 consent	
was obtained from all participants through the institutional review 
boards at participating centres.
Beginning	 in	 1994	 and	 continuing	 to	 the	 present,	 clinical,	 be-
havioural and biochemical end- points have been obtained annually 
during	 EDIC	 by	 history,	 physical	 examination	 and	 laboratory	 testing.	
Variables	 include	 smoking,	 BMI,	waist	 circumference,	 insulin	 dosage,	
medication	use	and	haemoglobin	A1c	(HbA1c).	The	EDIC	standardized	
annual history included a detailed interview regarding menstrual pat-
terns or discontinuation of menses, gynaecologic surgeries, and use of 
exogenous hormones, particularly oral contraceptive pill (OCP) use.17	At	
each of these annual interviews, women were asked “Since the last visit, 
has the patient had any changes to the conditions mentioned below?” 
“Irregular	menses”	was	 specifically	 listed	 as	 a	 condition,	 and	women	
were classified as having any history of irregular menses (yes/no).
Under a separate ancillary study mechanism, a sample of 415 women 





underwent up to 4 measures prior to menopause. For the purposes of this 
report, we examined the subset of women not using OCPS who had an 
AMH	measurement	 and	 a	 testosterone	measurement	 obtained	 during	
EDIC	years	1-	4,	when	women	were	on	average	36-	38	years	old.
Measurement	 of	 AMH	 concentrations	 was	 conducted	 by	 the	
EDIC	Central	Biochemistry	Laboratory	at	the	University	of	Minnesota	
(Minneapolis,	 MN)	 using	 a	 modified	 second-	generation	 enzyme-	
linked	 immunosorbent	 assay	 from	 Beckman	 Coulter	 (Webster,	
TX). The limit of quantification and limit of detection for the Gen 
II	AMH	assay	are	1.14	pmol/L	and	0.571	pmol/L,	 respectively.	The	
modified	Gen	II	assay	includes	a	predilution	step	which	avoids	inter-
ference with active complement binding.18	 In	 the	EDIC	 laboratory,	
the coefficients of variation were 8.1% at a mean concentration of 
23.46	pmol/L	 and	4.2%	at	 a	mean	 concentration	of	59.26	pmol/L.	
For values less than the limit of quantification but above the lower 
limit	of	detection,	SoftMax	Pro	software	 (Sunnyvale,	CA)	was	used	
to plot values, fit a cubic regression curve and create splines which 
were	then	used	to	calculate	AMH	concentrations.
Total	serum	testosterone	was	quantitated	at	the	EDIC	CBL	using	a	







testosterone concentrations and histories of irregular menses, as well 
as combinations of these reproductive abnormalities. Table 1 shows 
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the women’s baseline characteristics. There are currently no guide-
lines or recommendations regarding absolute cutpoints for elevations 
in	AMH7 or testosterone,19 only that the testosterone cutpoint should 
reflect the upper 2.5- 5th percentile of the distribution for women in 
the specific study population, which by definition precludes estimates 
of prevalence. Therefore, we used values identified as consistent with 
polycystic	 ovary	morphology	 (PCOM)	 obtained	 from	 another	 study	
of	women	with	type	1	diabetes	which	used	the	same	AMH	assay	as	
our	study.	In	the	study	by	Lebkowska	et	al20	an	AMH	concentration	
of	 26.70	pmol/L	 had	 the	 greatest	 area	 under	 the	 curve	 for	 PCOM	
(0.85,	95%	CI	0.73,	0.97)	with	90.2%	sensitivity	and	70.3%	specific-
ity	compared	to	transvaginal	ultrasound.	 In	that	study,	elevations	 in	
testosterone	 concentrations	 were	 defined	 as	 3.05	nmol/L,	 with	 an	
	interquartile	range	of	1.74-	3.82	nmol/L.20 Therefore, in our analysis, 
we	examined	 the	proportion	of	women	who	exceeded	1.74	nmol/L	
and	3.05	nmol/L	of	total	testosterone.
We examined the unadjusted associations between the initial 
AMH/testosterone	concentrations	in	EDIC	years	1-	4	and	other	vari-
ables	 measured	 concurrently	 (Table	2).	 Multivariable	 models	 were	
used to examine the adjusted associations between risk factors and 
AMH	or	testosterone	(Tables	S1	and	S2).	AMH	and	testosterone	con-
centrations were log- transformed for analysis. The per cent change in 
AMH	or	 testosterone	 concentration	per	 unit	 increase	 in	 concurrent	
risk	factor	or	the	per	cent	difference	in	the	mean	AMH	concentration	
is	presented.	HbA1c	levels	and	total	daily	insulin	dose	were	evaluated	




Table	1	 presents	 the	 participant	 characteristics	 at	 EDIC	 baseline.	






testosterone	 concentrations	 ≥1.74	nmol/L,	 and	 5	 (2.7%)	 had	 con-
centrations	≥3.05	nmol/L.	Sixteen	per	cent	of	women	had	at	least	2	
reproductive abnormalities, and only 7 women had irregular menses, 
elevations	in	AMH	and	elevations	in	testosterone.






testosterone	 concentrations.	AMH	 and	 testosterone	 concentrations	
were	not	significantly	associated	with	tertiles	of	BMI,	waist	circumfer-
ence, insulin dosage or glycemic control.
Tables	S1	and	S2	present	risk	factor	associations	with	AMH	and	
testosterone concentrations in multivariable linear regression models. 
Factors	associated	with	higher	AMH	concentrations	included	younger	
age, not smoking, lower insulin dosages and higher testosterone con-
centrations. Significant risk factors for testosterone included current 
smoking	 and	higher	AMH	concentrations.	Neither	AMH	nor	 testos-
terone concentrations were associated with irregular menses in mul-
tivariable	models.	In	multivariable	logistic	regression	models,	the	only	
variable associated with the presence of at least 2 reproductive abnor-
















Current smoking (n, %) 29 (16.0)
Irregular	menses	(n,	%) 37 (20.8)
Body	mass	index	(kg/m2) 26.5	±	4.2
Waist circumference (cm) 80.1	±	9.3





















or irregular menses (n, %)
30 (16.0)
aWomen	using	OCPs	at	the	time	of	AMH	and	testosterone	measurement	
were excluded, although 5 women were using OCPs at baseline but not at 
subsequent visits when testosterone was measured.
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more rapidly after 37 years of age.9 Few reports have examined 
abnormalities in ovarian markers in women with type 1 diabetes in 
this age range, although as many as a third of younger women with 
type	1	diabetes	may	have	PCOM	and	androgen	abnormalities.13	In	a	
relatively large cohort of well- phenotyped women with type 1 dia-
betes	with	a	median	age	of	35	years,	we	found	that	AMH	elevations	
TABLE  2 Mean	±	SD	initial	anti-	Müllerian	hormone	(AMH)	and	testosterone	concentrations	in	EDIC	years	1-	4	by	concurrent	risk	factors.	





P- valueN = 187 (pmol/L) N = 187 (nmol/L)
Age	(years)	
20- 29 years 37 47.9	±	35.9 <.0001 37 1.46	±	0.92 .17
30- 39 years 99 29.6	±	31.5 99 1.19	±	1.18
40- 50 years 51 12.9	±	20.9 51 1.04	±	0.67
Duration	of	diabetes	(years)
Tertile 1 (6- 11) 50 26.8	±	27.6 .59 50 1.32	±	1.57 .61
Tertile 2 (11- 17) 64 32.1	±	33.9 64 1.16	±	0.81
Tertile 3 (17- 26) 73 27.1	±	33.5 73 1.15	±	0.63
Oral conceptive use
Yes - - - - - 
No 187 28.7	±	32.1 187 1.20	±	1.02
Current smoking
Yes 28 19.9	±	27.4 .12 28 1.27	±	0.62 .68
No 159 30.2	±	32.7 159 1.19	±	1.07
History	of	irregular	menses
Yes 49 40.1	±	44.5 .004 49 1.26	±	0.82 .62
No 136 25.0	±	25.4 136 1.18	±	1.08
Body	mass	index	(kg/m2)
Tertile 1 (18.9- 23.7) 49 31.4	±	3185 .79 49 1.00	±	0.43 .26
Tertile 2 (23.7- 26.7) 62 27.5	±	34.0 62 1.27	±	1.41
Tertile 3 (26.7- 42.1) 76 27.9	±	31.1 76 1.28	±	0.89
Waist circumference (cm) 
Tertile 1 (59.8- 73.7) 46 20.7	±	26.0 .14 46 0.97	±	0.44 .08
Tertile 2 (73.8- 81.0) 62 32.5	±	34.2 62 1.14	±	0.49
Tertile 3 (81.1- 117.2) 79 30.4	±	33.2 79 1.38	±	1.45
Time- weigh4ted insulin dose (units/kg/day)
Tertile 1 (0.20- 0.58) 61 30.7	±	38.3 .76 61 1.23	±	1.46 .95
Tertile 2 (0.58- 0.74) 64 26.5	±	29.3 64 1.17	±	0.74
Tertile 3 (0.74- 1.39) 62 29.1	±	28.5 62 1.21	±	0.71
Time-	weighted	haemoglobin	A1c	(%)
Tertile 1 (5.6- 7.3) 56 27.8	±	31.0 .62 56 1.19	±	0.85 .89
Tertile 2 (7.4- 8.4) 65 26.4	±	29.4 65 1.16	±	0.58
Tertile 3 (8.5- 12.2) 66 31.7	±	35.7 66 1.25	±	1.42
AMH	(ng/mL)
Tertile 1 (0.04- 1.4) - 60 0.90	±	0.57 <.0001
Tertile 2 (1.5- 3.8) 63 1.05	±	0.62
Tertile 3 (3.9- 23.5) 64 1.63	±	1.44
Testosterone	(ng/dL)
Tertile 1 (2.8- 23.5) 61 16.1	±	20.5 <.0001 - 
Tertile 2 (23.5- 33.6) 59 22.3	±	21.1
Tertile 3 (33.6- 329.7) 67 45.8	±	40.6
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affected over one- third of the population, consistent with the pres-
ence	of	PCOM.	Elevations	 in	 testosterone	were	considerably	 less	
common.	Although	 almost	 1	 in	 5	women	 reported	 irregular	men-
ses, irregular menses were not correlated with ovarian markers. 
Therefore,	 elevations	 in	 AMH	 are	 common	 and	 could	 potentially	
explain decreased fecundity in women with type 1 diabetes, apart 
from irregular menses.
We	also	found	that	factors	associated	with	higher	AMH	included	
younger age, higher testosterone concentrations and not currently 
smoking as has been reported in other studies.21	In	contrast	to	other	
reports, we note that lower insulin doses over time were also cor-
related	with	higher	AMH	concentrations,	suggesting	that	 in	this	 late	
reproductive- age population, higher exogenous insulin does not act as 
a gonadotropin and thus does not result in elevations in ovarian mark-
ers. Previous reports conflict.20,22 We may have found different results 
due to the relatively older age of our population and our use of time- 
weighted variables, which accounts for longitudinal changes in insulin 
dosing over time, as opposed to previous cross- sectional analyses. We 
also included a significantly larger number of women than in previous 
reports, which included less than women with type 1 diabetes.20,22
The factors associated with higher testosterone concentration 
included	higher	AMH	and	a	history	of	smoking,	which	was	 likely	due	
to the fact that women using OCPs were excluded; thus, women who 
had testosterone measurement were younger and already more likely 
to smoke than women who did not have testosterone measurement. 
Due	to	the	presence	of	insulin	receptors	on	the	ovary	and	associations	
F IGURE  1 Scatterplot of age (years) 
vs	anti-	Müllerian	hormone	(AMH)	
concentrations	(pmol/L)	[Colour	figure	can	
be viewed at wileyonlinelibrary.com]
F IGURE  2 Scatterplot of age (years) 
vs total testosterone concentrations 
(nmol/L)	[Colour	figure	can	be	viewed	at	
wileyonlinelibrary.com]
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between	elevations	 in	testosterone	with	PCOM,	others	have	hypoth-
esized	that	exogenous	insulin	may	act	as	a	gonadotropin	in	type	1	di-
abetes.	 In	EDIC	women,	 insulin	did	not	appear	 to	be	associated	with	
elevated testosterone concentrations.23 This may be because the pres-
ence	of	significant	elevations	in	testosterone	was	rare	in	EDIC	women.	
In	addition,	previous	reports	note	that	among	women	with	known	hy-
perandrogenemia, androgen levels decline as women age particularly 
beginning in the 4th decade of life,24,25 which may also account for the 
lower androgen levels.
Neither	 AMH	 nor	 testosterone	 elevations	were	 correlated	with	
the prevalence of irregular menses, even though histories of irregu-
lar	menses	were	 common	 in	 the	EDIC	population	and	among	other	
cohorts of women with type 1 diabetes.26,27 Thus, irregular menses 
may independently contribute to decreased risk of fecundity apart 
from	these	pathways.	Multiple	endocrinologic	disorders	can	result	in	
irregular menses, including disorders that are more common in women 
with type 1 diabetes than in women without diabetes; we have previ-
ously	reported	that	the	risk	of	hypothyroidism	was	high	in	EDIC,	with	
approximately 25% of women noting hypothyroidism by the 18th year 
of	EDIC	follow-	up.6 Others have noted that women with type 1 diabe-
tes have abnormal gonadotropin- releasing hormone pulse generation 
which may also result in irregular menstrual cycles.28
Strengths	of	 this	 report	 include	 its	 large	and	well-	characterized	
population of women with type 1 diabetes who were of older age 
than in previous reports examining ovarian markers. We used an 
AMH	assay	with	higher	 sensitivity	and	precision	 than	presented	 in	
previous studies that used first- generation assays, which may be less 
subject to issues of performance and interpretation than transvag-
inal ultrasound.7 Testosterone was performed with mass spectrom-
etry, generally considered more sensitive than other methods,29 an 
issue particularly important in women. This report also has several 
limitations. The assessment of reproductive abnormalities was not 
a	primary	objective	of	 the	EDIC	 study,	 and	 thus,	women	were	not	
asked	 to	 record	 cycle	 length	with	menstrual	 diaries.	 EDIC	 did	 not	
conduct transvaginal ultrasounds to assess ovarian morphology nor 
clinical assessments of hyperandrogenism such as measurement 
of	 Ferriman-	Gallwey	 scores.	 Difficulties	 with	 fertility	 and	 actual	
thyroid hormone levels were not assessed. There are no universal 
cutpoints	 for	 abnormal	 levels	 of	AMH	 and	 testosterone.19 We ex-
amined cutpoints corresponding with the 25th percentile of total 
testosterone as well as with the 50th percentile compared to previ-
ous reports in younger populations, and thus, it is unlikely that lower 
cutpoints would lead to a significantly higher prevalence of hyper-
androgenism.20 Testosterone was assessed only in women not using 
OCPs, and it is possible that clinical hyperandrogenemia was masked 
among the 14% of women who were OCP users or that testoster-
one concentrations were less elevated among women who chose not 
to use OCPs, thus underestimating the proportion of women with 
hyperandrogenemia.
Finally,	 it	 is	 unknown	whether	 the	 relationships	 between	AMH,	
testosterone, irregular menses and PCOS differ between women 
with and without type 1 diabetes. We did not conduct a comparison 
between	 women	 with	 and	 without	 diabetes.	 In	 a	 previous	 report,	
we	noted	that	women	 in	EDIC	had	 lower	AMH	concentrations	than	
women in a control group and that these lower concentrations were 
primarily	attributable	to	a	slightly	lower	prevalence	of	elevated	AMH	
concentrations.18	Aside	from	the	comparison	of	women	in	EDIC	with	a	
control group, 2 previous reports have noted that women with type 1 
diabetes	had	slightly	lower	AMH	concentrations	than	women	without	
type 1 diabetes.20,30 Reports have conflicted as to whether testoster-
one concentrations differ between women with and without type 1 
diabetes.	Lebkowska	et	al.	noted	that	testosterone	levels	were	similar	
among 37 women with type 1 diabetes vs 42 women without diabe-
tes by PCOS status,20 and Soto et al.31 and Codner et al22 found that 
testosterone levels were similar in 28 women with type 1 diabetes 
and	18	women	without	diabetes.	In	contrast,	Salonia	et	al	found	that	
testosterone concentrations were higher among women with type 
1 diabetes (n = 50) than women without type 1 diabetes (n = 47),32 
and	Escobar-	Morreale	 et	al	 also	noted	 that	 testosterone	 concentra-
tions were higher among women with type 1 diabetes without PCOS 
(n = 52) compared to controls (n = 18).33
We conclude that the prevalence of abnormalities in ovarian mark-
ers,	 specifically	 elevations	 in	AMH,	 is	 common	 in	women	with	 type	
1 diabetes at an age where they are at increased risk for infertility. 
Irregular	menses	are	also	common	although	not	associated	with	AMH,	
and	elevations	 in	testosterone	are	relatively	uncommon.	 In	conjunc-
tion with previous reports noting decreased fecundity in women with 
type 1 diabetes, our findings can be used to guide pregnancy planning 
and fertility management in women with type 1 diabetes in their thir-
ties.	Additional	 investigation	of	 the	 reasons	 for	decreased	 fecundity	
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